Costanza Alciati, a pharma analyst at GlobalData, told BioSpace in an email that GLP-1s will definitely dominate the market in the near future, but new entrants into the space are already looking for the next drug class that could revolutionize the space. Companies taking an alternative approach are forecast to capture only a very small portion of the obesity marketroughly 6.3%across the seven major markets (U.S., France, Germany, Italy, Spain, UK and Japan) by the end of 2031, according to Sara Reci, a senior analyst at GlobalData
How to Avoid Very Rapid Weight Loss When Using GLP-1 Drugs If your weight drops faster than expected, tell your clinician
Traditionally what we would see is that when there becomes an oral option, people would switch to it
Yes, condor flights in Colca happen almost every day, especially between 6:30 and 9:00 a.m., when the thermal currents allow them to rise
Immunotherapies belong to the field of research in which the development of specific inhibitors or regulators presents the most significant advances in therapy development
Med 389 , 877888 (2023)
.png)
